Canaccord Genuity Starts Entellus Medical (ENTL) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Piper Jaffray Starts Entellus Medical (ENTL) at Overweight
February 23, 2015 6:51 AM ESTPiper Jaffray initiates coverage on Entellus Medical (NASDAQ: ENTL) with a Overweight rating and a price target of $25.00.
Analyst Thomas Gunderson comments, "We are initiating ENTL with an Overweight rating and $25 price target. Entellus, a manufacturer and marketer of a balloon dilation product line for... More
BofA/Merrill Lynch Starts Entellus Medical (ENTL) at Buy
February 23, 2015 6:24 AM ESTBofA/Merrill Lynch initiates coverage on Entellus Medical (NASDAQ: ENTL) with a Buy rating and a price target of $26.00.
Analyst Bob Hopkins is bullish on the company's minimally invasive balloon-based alternative to open surgery for treating chronic sinusitis. The device allows doctors to... More
